Abstract | OBJECTIVE: DESIGN: Raw data from these two randomized, placebo-controlled trials evaluating second-generation antidepressants for hot flashes were obtained. These data and subsequent study conclusions are evaluated and discussed in the context of other published trial data regarding the use of newer antidepressants for treating hot flashes. RESULTS: Examination of the raw data from these two trials revealed that neither employed a baseline period of hot flash determination against which to calculate changes over time from baseline. CONCLUSIONS: Recognition that these two trials cannot be used to look at hot flash frequency or score changes from baseline limits their ability to inform the efficacy literature about the use of newer antidepressants for hot flash reduction.
|
Authors | Charles L Loprinzi, Debra L Barton, Jeff A Sloan, Paul J Novotny, Sherry Wolf |
Journal | Menopause (New York, N.Y.)
(Menopause)
2009 Jan-Feb
Vol. 16
Issue 1
Pg. 184-7
ISSN: 1530-0374 [Electronic] United States |
PMID | 18725865
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antidepressive Agents, Second-Generation
- Cyclohexanols
- Placebos
- Fluoxetine
- Citalopram
- Venlafaxine Hydrochloride
|
Topics |
- Antidepressive Agents, Second-Generation
(therapeutic use)
- Citalopram
(therapeutic use)
- Cyclohexanols
(therapeutic use)
- Double-Blind Method
- Female
- Fluoxetine
(therapeutic use)
- Hot Flashes
(drug therapy)
- Humans
- Placebos
- Randomized Controlled Trials as Topic
- Treatment Outcome
- Venlafaxine Hydrochloride
|